Ocular Hypertension News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

Can Rhopressa's Approval Drive Aerie (AERI) in Q4 Earnings? - Nasdaq



Nasdaq
 
Can Rhopressa's Approval Drive Aerie (AERI) in Q4 Earnings? 
Nasdaq
The drug can lower elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Since Aerie did not have any approved glaucoma product in its portfolio and given the potential the market holds, the news came as a major ...

and more » 


New glaucoma drugs yield large, lasting reductions in intraocular pressure - Medical Xpress



Medical Xpress
 
New glaucoma drugs yield large, lasting reductions in intraocular pressure 
Medical Xpress
LBN, applied topically, reduces pressure in the eye of patients with open-angle glaucoma or ocular hypertension via two mechanisms, latanoprost-mediated increase in unconventional outflow and nitric oxide-mediated increase in conventional outflow ...

and more » 


Head-To-Head Analysis: Atrion (ATRI) and Ocular Therapeutix (OCUL) - Dispatch Tribunal



Head-To-Head Analysis: Atrion (ATRI) and Ocular Therapeutix (OCUL) 
Dispatch Tribunal
Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase ...

 


Latanoprost Market Trends Forecast Analysis by Manufacturers, Regions, Type and Application to 2023 - Facts of Week



Latanoprost Market Trends Forecast Analysis by Manufacturers, Regions, Type and Application to 2023 
Facts of Week
Latanoprost is used to treat high pressure inside the eye due to glaucoma (open angle type) or other eye diseases (e.g., ocular hypertension). It is similar to a natural chemical in the body (prostaglandin) and works by regulating the flow of fluid ...

and more » 


Comparing Ocular Therapeutix (OCUL) and Haemonetics (HAE) - StockNewsTimes



Comparing Ocular Therapeutix (OCUL) and Haemonetics (HAE) 
StockNewsTimes
Its lead product candidate, DEXTENZA (dexamethasone insert) for intracanalicular use, has completed Phase III clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP (travoprost insert) is in Phase ...

and more » 


Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on ... - Business Wire (press release)



Business Wire (press release)
 
Aerie Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on ... 
Business Wire (press release)
Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was approved by the U.S. Food and Drug Administration (FDA ...
Today Aerie Pharmaceuticals Inc (NASDAQ:AERI) Reported Decrease in Shorted Shares BZ Weekly
Zacks Investment Research Lowers Aerie Pharmaceuticals (NASDAQ:AERI) to Sell Dispatch Tribunal
Financial Newsletter - Zacks Zacks
Zacks 
all 51 news articles » 


Krensavage Asset Management Llc Decreased Sucampo Pharmaceuticals (NASDAQ:SCMP) Stake By $25.99 Million - BZ Weekly



Krensavage Asset Management Llc Decreased Sucampo Pharmaceuticals (NASDAQ:SCMP) Stake By $25.99 Million 
BZ Weekly
The company's marketed product includes AMITIZA , a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced ...

and more » 


First in Class Drug for Glaucoma: What Pharmacists Need to Know - ModernMedicine



Weekly Register
 
First in Class Drug for Glaucoma: What Pharmacists Need to Know 
ModernMedicine
For the first time in more than a decade, a new drug class has been introduced for treatment of glaucoma. Netarsudil opthalmic solution (Rhopressa, Aerie Pharmaceuticals, Inc.) is a first-in-class once-daily therapy that presents another option for ...
Aerie Pharmaceuticals Announces Appointment of Scott Cassady as Regional Sales Director for the Central Region Business Wire (press release)
Learn Why Flynn James E Purchased Aerie Pharmaceuticals Inc Stake? Frisco Fastball
Aerie Pharmaceuticals (NASDAQ:AERI) Rating Lowered to Sell at Zacks Investment Research StockNewsTimes
Press Telegraph  -Zacks  -Zacks 
all 50 news articles » 


Ocular Therapeutix? to Participate in the 2018 Glaucoma 360 Meeting in San Francisco - Business Wire (press release)



Ocular Therapeutix? to Participate in the 2018 Glaucoma 360 Meeting in San Francisco 
Business Wire (press release)
Ocular Therapeutix's lead product candidate, DEXTENZA? (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP ...

and more » 


Ocular Therapeutix? Announces Proposed Public Offering of Common Stock - Business Wire (press release)



Ocular Therapeutix? Announces Proposed Public Offering of Common Stock 
Business Wire (press release)
Ocular Therapeutix's lead product candidate, DEXTENZA? (dexamethasone insert) 0.4 mg for intracanalicular use, has completed Phase 3 clinical development for the treatment of ocular pain and inflammation following ophthalmic surgery. OTX-TP ...

and more »